Home > Healthcare > Medical Devices > Diagnostic Devices > Central Nervous System Biomarkers Market

Central Nervous System Biomarkers Market Trends

  • Report ID: GMI8335
  • Published Date: Feb 2024
  • Report Format: PDF

Central Nervous System Biomarkers Market Trends

Increasing use of CNS biomarkers is a significant driver for the market. They offer the potential for earlier detection and more accurate diagnosis of neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, among others.

  • In the development of new drugs for CNS disorders, biomarkers are essential for patient stratification, monitoring treatment response, and assessing drug efficacy. Biotechnology companies are increasingly using biomarkers as endpoints in clinical trials, speeding up the drug development process and reducing costs.
  • For instance, according to Springer Nature, in 2020, there were various neurological biomarkers being utilized in the disease screening and interpretation, such as amyloid, tau, and synuclein, in the diagnosis of Alzheimer’s disease.
  • As research advances, new and more specific biomarkers are being discovered, allowing for more precise identification of these diseases in their early stages. Consequently, leading to increased use by researchers, clinicians, and scientists for improved disease management, drug development, and patient care in the field of neurology.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Central nervous system biomarkers market size was USD 5.6 billion in 2023 and is expected to register 8.1% CAGR from 2024-2032 owing to the increasing prevalence of neurological disorders worldwide.

The safety biomarker segment recorded USD 2.5 billion in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their significance in clinical trials to monitor and assess the safety profile of new drugs.

North America central nervous system biomarkers industry reached USD 2.3 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the presence of the world's leading research institutions focused on neuroscience and biomarker development in the region.

F. Hoffmann-La Roche Ltd, G-Biosciences, Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., Novartis AG, PerkinElmer Inc., Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific Inc., are some of the major central nervous system biomarkers companies worldwide.

Central Nervous System Biomarkers Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 215
  • Countries covered: 22
  • Pages: 160
 Download Free Sample